Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium
- PMID: 23404857
- PMCID: PMC3857135
- DOI: 10.1530/ERC-12-0395
Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium
Abstract
Whilst previous studies have reported that higher BMI increases a woman's risk of developing ovarian cancer, associations for the different histological subtypes have not been well defined. As the prevalence of obesity has increased dramatically, and classification of ovarian histology has improved in the last decade, we sought to examine the association in a pooled analysis of recent studies participating in the Ovarian Cancer Association Consortium. We evaluated the association between BMI (recent, maximum and in young adulthood) and ovarian cancer risk using original data from 15 case-control studies (13 548 cases and 17 913 controls). We combined study-specific adjusted odds ratios (ORs) using a random-effects model. We further examined the associations by histological subtype, menopausal status and post-menopausal hormone use. High BMI (all time-points) was associated with increased risk. This was most pronounced for borderline serous (recent BMI: pooled OR=1.24 per 5 kg/m(2); 95% CI 1.18-1.30), invasive endometrioid (1.17; 1.11-1.23) and invasive mucinous (1.19; 1.06-1.32) tumours. There was no association with serous invasive cancer overall (0.98; 0.94-1.02), but increased risks for low-grade serous invasive tumours (1.13, 1.03-1.25) and in pre-menopausal women (1.11; 1.04-1.18). Among post-menopausal women, the associations did not differ between hormone replacement therapy users and non-users. Whilst obesity appears to increase risk of the less common histological subtypes of ovarian cancer, it does not increase risk of high-grade invasive serous cancers, and reducing BMI is therefore unlikely to prevent the majority of ovarian cancer deaths. Other modifiable factors must be identified to control this disease.
Conflict of interest statement
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
References
-
- Balogun N, Gentry-Maharaj A, Wozniak EL, Lim A, Ryan A, Ramus SJ, Ford J, Burnell M, Widschwendter M, Gessler SF, et al. Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. J Clin Epidemiol. 2011;64:525–530. - PubMed
-
- Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–591. - PubMed
-
- Cramer SF, Roth LM, Ulbright TM, Mazur MT, Nunez CA, Gersell DJ, Mills SE, Kraus FT. Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers. With emphasis on methodology. Arch Pathol Lab Med. 1987;111:819–829. - PubMed
Publication types
MeSH terms
Grants and funding
- R01 CA83918/CA/NCI NIH HHS/United States
- R01 CA136891/CA/NCI NIH HHS/United States
- N01 PC067010/PC/NCI NIH HHS/United States
- R01 CA087538/CA/NCI NIH HHS/United States
- CA14089/CA/NCI NIH HHS/United States
- 5R01 CA074850/CA/NCI NIH HHS/United States
- R01 CA61107/CA/NCI NIH HHS/United States
- R01 CA080742/CA/NCI NIH HHS/United States
- K07 CA092044/CA/NCI NIH HHS/United States
- P50 CA105009/CA/NCI NIH HHS/United States
- CA63464/CA/NCI NIH HHS/United States
- P30 CA008748/CA/NCI NIH HHS/United States
- N01 PC35137/PC/NCI NIH HHS/United States
- P01 CA017054/CA/NCI NIH HHS/United States
- N01 PC67010/PC/NCI NIH HHS/United States
- CA054419-10/CA/NCI NIH HHS/United States
- N01 PC035137/PC/NCI NIH HHS/United States
- P40 CA1005009/CA/NCI NIH HHS/United States
- R01 CA87538/CA/NCI NIH HHS/United States
- R03 CA113148/CA/NCI NIH HHS/United States
- R01 CA058598/CA/NCI NIH HHS/United States
- K22 CA138563/CA/NCI NIH HHS/United States
- R01 CA058860/CA/NCI NIH HHS/United States
- R01 CA76016/CA/NCI NIH HHS/United States
- CA92044/CA/NCI NIH HHS/United States
- R01 CA074850/CA/NCI NIH HHS/United States
- P30 CA014089/CA/NCI NIH HHS/United States
- CA17054/CA/NCI NIH HHS/United States
- R01 CA083918/CA/NCI NIH HHS/United States
- R01 CA063464/CA/NCI NIH HHS/United States
- N01 CN67001/CN/NCI NIH HHS/United States
- CA58860/CA/NCI NIH HHS/United States
- R01 CA054419/CA/NCI NIH HHS/United States
- R01-CA-122443/CA/NCI NIH HHS/United States
- R01 CA122443/CA/NCI NIH HHS/United States
- R01 CA076016/CA/NCI NIH HHS/United States
- 5R01 CA080742/CA/NCI NIH HHS/United States
- U01 CA063464/CA/NCI NIH HHS/United States
- ImNIH/Intramural NIH HHS/United States
- R01 CA13689101A1/CA/NCI NIH HHS/United States
- CA61132/CA/NCI NIH HHS/United States
- U01 CA058860/CA/NCI NIH HHS/United States
- R01 CA58598/CA/NCI NIH HHS/United States
- K07 CA095666/CA/NCI NIH HHS/United States
- R01 CA112523/CA/NCI NIH HHS/United States
- P50 CA136393/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
